Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

$3.9B

Market Cap • 4/3/2025

2013

(12 years)

Founded

2020

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of US

San Carlos

Headquarters • California